362 related articles for article (PubMed ID: 17082468)
1. A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease.
Aisen PS; Saumier D; Briand R; Laurin J; Gervais F; Tremblay P; Garceau D
Neurology; 2006 Nov; 67(10):1757-63. PubMed ID: 17082468
[TBL] [Abstract][Full Text] [Related]
2. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial.
Freund-Levi Y; Eriksdotter-Jönhagen M; Cederholm T; Basun H; Faxén-Irving G; Garlind A; Vedin I; Vessby B; Wahlund LO; Palmblad J
Arch Neurol; 2006 Oct; 63(10):1402-8. PubMed ID: 17030655
[TBL] [Abstract][Full Text] [Related]
3. Intranasal insulin improves cognition and modulates beta-amyloid in early AD.
Reger MA; Watson GS; Green PS; Wilkinson CW; Baker LD; Cholerton B; Fishel MA; Plymate SR; Breitner JC; DeGroodt W; Mehta P; Craft S
Neurology; 2008 Feb; 70(6):440-8. PubMed ID: 17942819
[TBL] [Abstract][Full Text] [Related]
4. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.
Lannfelt L; Blennow K; Zetterberg H; Batsman S; Ames D; Harrison J; Masters CL; Targum S; Bush AI; Murdoch R; Wilson J; Ritchie CW;
Lancet Neurol; 2008 Sep; 7(9):779-86. PubMed ID: 18672400
[TBL] [Abstract][Full Text] [Related]
5. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results.
Sparks DL; Sabbagh MN; Connor DJ; Lopez J; Launer LJ; Browne P; Wasser D; Johnson-Traver S; Lochhead J; Ziolwolski C
Arch Neurol; 2005 May; 62(5):753-7. PubMed ID: 15883262
[TBL] [Abstract][Full Text] [Related]
6. Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study.
Hampel H; Ewers M; Bürger K; Annas P; Mörtberg A; Bogstedt A; Frölich L; Schröder J; Schönknecht P; Riepe MW; Kraft I; Gasser T; Leyhe T; Möller HJ; Kurz A; Basun H
J Clin Psychiatry; 2009 Jun; 70(6):922-31. PubMed ID: 19573486
[TBL] [Abstract][Full Text] [Related]
7. AMPA potentiator treatment of cognitive deficits in Alzheimer disease.
Chappell AS; Gonzales C; Williams J; Witte MM; Mohs RC; Sperling R
Neurology; 2007 Mar; 68(13):1008-12. PubMed ID: 17389305
[TBL] [Abstract][Full Text] [Related]
8. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial.
Ritchie CW; Bush AI; Mackinnon A; Macfarlane S; Mastwyk M; MacGregor L; Kiers L; Cherny R; Li QX; Tammer A; Carrington D; Mavros C; Volitakis I; Xilinas M; Ames D; Davis S; Beyreuther K; Tanzi RE; Masters CL
Arch Neurol; 2003 Dec; 60(12):1685-91. PubMed ID: 14676042
[TBL] [Abstract][Full Text] [Related]
9. Selegiline in the treatment of Alzheimer's disease: a long-term randomized placebo-controlled trial. Czech and Slovak Senile Dementia of Alzheimer Type Study Group.
Filip V; Kolibás E
J Psychiatry Neurosci; 1999 May; 24(3):234-43. PubMed ID: 10354658
[TBL] [Abstract][Full Text] [Related]
10. A neuropsychological test battery for use in Alzheimer disease clinical trials.
Harrison J; Minassian SL; Jenkins L; Black RS; Koller M; Grundman M
Arch Neurol; 2007 Sep; 64(9):1323-9. PubMed ID: 17846273
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
Wilcock GK; Black SE; Hendrix SB; Zavitz KH; Swabb EA; Laughlin MA;
Lancet Neurol; 2008 Jun; 7(6):483-93. PubMed ID: 18450517
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease.
Burns A; Gauthier S; Perdomo C
Int J Geriatr Psychiatry; 2007 Aug; 22(8):806-12. PubMed ID: 17199235
[TBL] [Abstract][Full Text] [Related]
13. Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis.
Gervais F; Paquette J; Morissette C; Krzywkowski P; Yu M; Azzi M; Lacombe D; Kong X; Aman A; Laurin J; Szarek WA; Tremblay P
Neurobiol Aging; 2007 Apr; 28(4):537-47. PubMed ID: 16675063
[TBL] [Abstract][Full Text] [Related]
14. CSF biomarkers in relationship to cognitive profiles in Alzheimer disease.
van der Vlies AE; Verwey NA; Bouwman FH; Blankenstein MA; Klein M; Scheltens P; van der Flier WM
Neurology; 2009 Mar; 72(12):1056-61. PubMed ID: 19307538
[TBL] [Abstract][Full Text] [Related]
15. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Abeta production by NF-kappaB inhibitors.
Paris D; Patel N; Quadros A; Linan M; Bakshi P; Ait-Ghezala G; Mullan M
Neurosci Lett; 2007 Mar; 415(1):11-6. PubMed ID: 17223266
[TBL] [Abstract][Full Text] [Related]
17. An open-label study to evaluate the safety, tolerability and efficacy of rivastigmine in patients with mild to moderate probable Alzheimer's disease in the community setting.
Bilikiewicz A; Opala G; Podemski R; Puzyński S; Łapin J; Sołtys K; Ochudło S; Barcikowska M; Pfeffer A; Bilińska M; Paradowski B; Parnowski T; Gabryelewicz T
Med Sci Monit; 2002 Feb; 8(2):PI9-15. PubMed ID: 11859291
[TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.
Fagan AM; Roe CM; Xiong C; Mintun MA; Morris JC; Holtzman DM
Arch Neurol; 2007 Mar; 64(3):343-9. PubMed ID: 17210801
[TBL] [Abstract][Full Text] [Related]
19. Galantamine protects against oxidative stress induced by amyloid-beta peptide in cortical neurons.
Melo JB; Sousa C; Garção P; Oliveira CR; Agostinho P
Eur J Neurosci; 2009 Feb; 29(3):455-64. PubMed ID: 19222556
[TBL] [Abstract][Full Text] [Related]
20. Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease.
Siemers ER; Friedrich S; Dean RA; Gonzales CR; Farlow MR; Paul SM; Demattos RB
Clin Neuropharmacol; 2010; 33(2):67-73. PubMed ID: 20375655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
